Biopharmaceuticals are rapidly integrating remote patient monitoring and digital biomarkers into Phase II and III trials. The methodological evolution directly addresses historical recruitment bottlenecks and elevated drop-out rates.
Data Fidelity and Compliance
Continuous biometric data collection offers higher statistical validity than periodic in-clinic evaluations. Regulatory bodies have issued updated frameworks supporting synthetic control groups, further shortening market entry timelines for high-priority therapies.